Search Results for "Pertuzumab"
Original Source: Pertuzumab: In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer.
The humanized monoclonal antibody pertuzumab is the first in a new class of drugs, the human epidermal growth factor receptor (HER) dimerization inhibitors. Given that pertuzumab binds to a different epitope of the HER2 extracellular domain than trastuzumab, combination therapy with pertuzumab plus trastuzumab may result in more comprehensive blockade of HER2 signalling than can be achieved with trastuzumab alone. The efficacy of adding pertuzumab to trastuzumab plus docetaxel for the first-line treatment o...
Matching Channels
None
Matching News
Pertuzumab Wins FDA Nod for Breast Cancer
(MedPage Today) -- Pertuzumab is to be used with trastuzumab and chemotherapy in previously untreated HER2-positive metastatic disease.
Survival data show benefit of pertuzumab in breast cancer
Combining the new anticancer drug pertuzumab with trastuzumab and docetaxel improves survival for patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer, resu...
Pertuzumab Approved to Treat Some Metastatic Breast Cancers
The Food and Drug Administration (FDA) has approved pertuzumab (Perjeta) to treat women with HER2-positive breast cancer that has spread to other parts of the body. Pertuzumab is approved for use in c...
Pertuzumab available for HER2-positive breast cancer
Pertuzumab, a new breast cancer treatment for those with advanced human epidermal growth factor (HER)2-positive disease, is now available in the UK. Marketed by Roche as Perjeta, pertuzumab is ind...
Pertuzumab filed for breast cancer in Japan
Roche's subsidiary Chugai has made an approval filing in Japan for Genentech/Roche's HER-dimerisation inhibitor pertuzumab, for the treatment of HER2-positive metastatic or recurrent breast cancer....
Perjeta (pertuzumab) extends survival in HER2-positive breast cancer
ZURICH (Reuters) - Swiss pharma group Roche's drug Perjeta (pertuzumab) significantly extended the lives of women with HER2-positive breast cancer compared to a placebo, according to new data from...
FDA approves pertuzumab for breast cancer
FDA approved a BLA from Genentech Inc. for Perjeta pertuzumab to treat previously untreated HER2-positive metastatic breast cancer in combination with Herceptin trastuzumab and docetaxel. Genentech, a...
Matching PubMed Articles
Pertuzumab: In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer.
The humanized monoclonal antibody pertuzumab is the first in a new class of drugs, the human epidermal growth factor receptor (HER) dimerization inhibitors. Given that pertuzumab binds to a different...
Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.
Introduction: HER2 overexpression or amplification is present in approximately one-fifth of breast cancers and historically was associated with aggressive disease and poorer prognosis. The introductio...
Purpose Resistance to cetuximab, a monoclonal antibody against the epithelial growth factor receptor (EGFR), in colorectal cancer (CRC) may result from compensatory signaling through ErbB receptors, E...
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
The anti-human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of...
